{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:46:42Z","timestamp":1793641602548,"version":"4.5.1"},"reference-count":76,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,2]],"date-time":"2023-04-02T00:00:00Z","timestamp":1680393600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","fertstert.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Fertility and Sterility"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.fertnstert.2022.01.029","type":"journal-article","created":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T07:27:55Z","timestamp":1646465275000},"page":"657-663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pretreatment: Does it improve quantity or quality?"],"prefix":"10.1016","volume":"117","author":[{"given":"Raoul","family":"Orvieto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fertnstert.2022.01.029_bib1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3109\/09513599409023632","article-title":"The poor-responder patient in an in\u00a0vitro fertilization-embryo transfer (IVF-ET) program","volume":"8","author":"Ben-Rafael","year":"1994","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0015-0282(99)00630-5","article-title":"Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques","volume":"73","author":"Surrey","year":"2000","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib3","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0015-0282(01)03280-0","article-title":"Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders","volume":"77","author":"Mitwally","year":"2002","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib4","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1093\/humrep\/des318","article-title":"Live birth rates following natural cycle IVF in women with poor ovarian response according to the Bologna criteria","volume":"27","author":"Polyzos","year":"2012","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib5","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.fertnstert.2007.06.022","article-title":"Ultrashort gonadotropin-releasing hormone agonist combined with flexible multidose gonadotropin-releasing hormone antagonist for poor responders in in\u00a0vitro fertilization\/embryo transfer programs","volume":"90","author":"Orvieto","year":"2008","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib6","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.fertnstert.2014.02.036","article-title":"Is the modified natural in\u00a0vitro fertilization cycle justified in patients with \"genuine\" poor response to controlled ovarian hyperstimulation?","volume":"101","author":"Kedem","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib7","first-page":"118","article-title":"Do poor-responder patients benefit from increasing the daily gonadotropin dose from 300 to 450 IU during controlled ovarian hyperstimulation for IVF?","volume":"154","author":"Haas","year":"2015","journal-title":"Harefuah"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib8","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/humrep\/dex208","article-title":"Efficacy and safety of follitropin alfa\/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders","volume":"32","author":"Humaidan","year":"2017","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib9","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3389\/fendo.2020.00182","article-title":"Stop GnRH-agonist combined with multiple-dose GnRH-antagonist protocol for patients with \"genuine\" poor response undergoing controlled ovarian hyperstimulation for IVF","volume":"11","author":"Orvieto","year":"2020","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.rbmo.2017.09.016","article-title":"Insights from clinical experience in treating IVF poor responders","volume":"36","author":"Gonda","year":"2018","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib11","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.fertnstert.2011.09.050","article-title":"Androgens and poor responders: are we ready to take the plunge into clinical therapy?","volume":"96","author":"Fanchin","year":"2011","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1477-7827-9-67","article-title":"Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR)","volume":"9","author":"Gleicher","year":"2011","journal-title":"Reprod Biol Endocrinol"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib13","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1172\/JCI2081","article-title":"Androgens stimulate early stages of follicular growth in the primate ovary","volume":"101","author":"Vendola","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib14","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1210\/jcem.83.7.4917","article-title":"Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations","volume":"83","author":"Weil","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0950-3552(97)80036-3","article-title":"Role of androgens in follicle maturation and atresia","volume":"11","author":"Hillier","year":"1997","journal-title":"Baillieres Clin Obstet Gynaecol"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib16","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.rbmo.2012.07.011","article-title":"Effects of transdermal testosterone in poor responders undergoing IVF: systematic review and meta-analysis","volume":"25","author":"Gonz\u00e1lez-Comadran","year":"2012","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib17","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/humrep\/dew028","article-title":"Transdermal testosterone pretreatment in poor responders undergoing ICSI: a randomized clinical trial","volume":"31","author":"Bosdou","year":"2016","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib18","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.rbmo.2021.05.021","article-title":"Testosterone does not improve ovarian response in Bologna poor responders: a randomized controlled trial (TESTOPRIM)","volume":"43","author":"Subir\u00e1","year":"2021","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/rmb2.12383","article-title":"Therapeutic effect\u00a0of prolonged testosterone pretreatment in women with poor ovarian response: a randomized control trial","volume":"20","author":"Hoang","year":"2021","journal-title":"Reprod Med Biol"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.653857","article-title":"The role of androgen supplementation in women with diminished ovarian reserve: time to randomize, not meta-analyze","volume":"12","author":"Neves","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib21","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.rbmo.2010.04.006","article-title":"Improvement in diminished ovarian reserve after dehydroepiandrosterone supplementation","volume":"21","author":"Gleicher","year":"2010","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib22","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1477-7827-8-140","article-title":"Dehydroepiandrosterone (DHEA) reduces embryo aneuploidy: direct evidence from preimplantation genetic screening (PGS)","volume":"8","author":"Gleicher","year":"2010","journal-title":"Reprod Biol Endocrinol"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib23","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/humrep\/15.10.2129","article-title":"Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series","volume":"15","author":"Casson","year":"2000","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib24","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1093\/humrep\/del254","article-title":"Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF","volume":"21","author":"Barad","year":"2006","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib25","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.rbmo.2009.06.006","article-title":"Dehydroepiandrosterone supplementation improves ovarian response and cycle outcome in poor responders","volume":"19","author":"Sonmezer","year":"2009","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib26","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12958-018-0409-z","article-title":"Dehydroepiandrosterone (DHEA) supplementation improves in\u00a0vitro fertilization outcomes of poor ovarian responders, especially in women with low serum concentration of DHEA-S: a retrospective cohort study","volume":"16","author":"Chern","year":"2018","journal-title":"Reprod Biol Endocrinol"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib27","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s10815-016-0713-5","article-title":"Dehydroepiandrosterone treatment in women with poor ovarian response undergoing IVF or ICSI: a systematic review and meta-analysis","volume":"33","author":"Zhang","year":"2016","journal-title":"J Assist Reprod Genet"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1477-7827-3-54","article-title":"The role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment","volume":"3","author":"Mitwally","year":"2005","journal-title":"Reprod Biol Endocrinol"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib29","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1093\/humrep\/del221","article-title":"Androgen priming using aromatase inhibitor and hCG during early-follicular-phase GnRH antagonist down-regulation in modified antagonist protocols","volume":"21","author":"Lossl","year":"2006","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib30","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/humrep\/deh369","article-title":"Recombinant human LH supplementation during GnRH antagonist administration in IVF\/ICSI cycles: a prospective randomized study","volume":"19","author":"C\u00e9drin-Durnerin","year":"2004","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1477-7827-7-91","article-title":"\"hCG priming\" effect in controlled ovarian stimulation through a long protocol","volume":"7","author":"Beretsos","year":"2009","journal-title":"Reprod Biol Endocrinol"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib32","first-page":"52","article-title":"Andro-IVF: a novel protocol for poor responders to IVF controlled ovarian stimulation","volume":"22","author":"Bercaire","year":"2018","journal-title":"JBRA Assist Reprod"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib33","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.rbmo.2019.11.005","article-title":"The effect of intra-ovarian androgen priming on ovarian reserve parameters in Bologna poor responders","volume":"40","author":"Vuong","year":"2020","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib34","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/j.fertnstert.2003.11.037","article-title":"Premenstrual administration of gonadotropin-releasing hormone antagonist coordinates early antral follicle sizes and sets up the basis for an innovative concept of controlled ovarian hyperstimulation","volume":"81","author":"Fanchin","year":"2004","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib35","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1093\/humrep\/deg516","article-title":"Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists","volume":"18","author":"Fanchin","year":"2003","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib36","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.fertnstert.2010.07.1058","article-title":"Luteal phase estradiol versus luteal phase estradiol and antagonist protocol for controlled ovarian stimulation before in\u00a0vitro fertilization in poor responders","volume":"95","author":"Elassar","year":"2011","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib37","doi-asserted-by":"crossref","first-page":"828","DOI":"10.3109\/00016341003721029","article-title":"Ganirelix for luteolysis in poor responder patients undergoing IVF treatment: a Scandinavian multicenter \u2018extended pilot study\u2019","volume":"89","author":"Nilsson","year":"2010","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib38","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1472-6483(10)61115-7","article-title":"Hormonal manipulations in the luteal phase to coordinate subsequent antral follicle growth during ovarian stimulation","volume":"10","author":"Fanchin","year":"2005","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib39","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S1472-6483(10)61685-9","article-title":"Reproductive outcome using a GnRH antagonist (cetrorelix) for luteolysis and follicular synchronization in poor responder IVF\/ICSI patients treated with a flexible GnRH antagonist protocol","volume":"11","author":"Humaidan","year":"2005","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib40","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.repbio.2017.01.006","article-title":"GnRH antagonist and letrozole co-treatment in diminished ovarian reserve patients: a proof-of-concept study","volume":"17","author":"Olgan","year":"2017","journal-title":"Reprod Biol"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib41","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/09513590.2012.736558","article-title":"Effects of luteal estradiol pre-treatment on the outcome of IVF in poor ovarian responders","volume":"29","author":"Chang","year":"2013","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib42","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1093\/humrep\/det306","article-title":"Cycle cancellation and pregnancy after luteal estradiol priming in women defined as poor responders: a systematic review and meta-analysis","volume":"28","author":"Reynolds","year":"2013","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib43","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.fertnstert.2014.01.050","article-title":"A novel \u2018\u2018delayed start\u2019\u2019 protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders","volume":"101","author":"Cakmak","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib44","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/09513590.2021.1918664","article-title":"Effects of oral contraceptive for different responder women before GnRH antagonists: a systematic review and meta-analysis","volume":"37","author":"Li","year":"2021","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib45","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1210\/edrv-6-3-400","article-title":"Insulin-like growth factors as intra-ovarian regulators of granulosa cell growth and functions","volume":"6","author":"Adashi","year":"1985","journal-title":"Endocr Rev"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib46","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2265.1988.tb00252.x","article-title":"Growth hormone facilitates ovulation induction by gonadotrophins","volume":"29","author":"Homburg","year":"1988","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib47","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0306-9877(97)90088-8","article-title":"A new concept of cotreatment with human growth hormone and menotropins in ovulation induction protocols","volume":"49","author":"Orvieto","year":"1997","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib48","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10815-008-9212-7","article-title":"Growth hormone co-treatment within a GnRH agonist long protocol in patients with poor ovarian response: a prospective, randomized, clinical trial","volume":"25","author":"Kucuk","year":"2008","journal-title":"J Assist Reprod Genet"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib49","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00404-012-2655-1","article-title":"Adjuvant growth hormone therapy in antagonist protocol in poor responders undergoing assisted reproductive technology","volume":"287","author":"Eftekhar","year":"2013","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib50","first-page":"565","article-title":"Low-dose growth hormone supplementation increases clinical pregnancy rate in poor responders undergoing in\u00a0vitro fertilisation","volume":"31","author":"Lattes","year":"2015","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib51","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/reprodmed2040016","article-title":"A 10-year perspective on the utility of three adjuvants often used in IVF: growth hormone, melatonin and DHEA","volume":"2","author":"Yovich","year":"2021","journal-title":"Reprod Med"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib52","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/acel.12368","article-title":"Coenzyme Q10 restores oocyte mitochondrial function and fertility during reproductive aging","volume":"14","author":"Ben-Meir","year":"2015","journal-title":"Aging Cell"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib53","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.fertnstert.2020.04.002","article-title":"Coenzyme Q10 supplementation of human oocyte in\u00a0vitro maturation reduces postmeiotic aneuploidies","volume":"114","author":"Ma","year":"2020","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4137\/CMRH.S14681","article-title":"Coenzyme Q10 supplementation and oocyte aneuploidy in women undergoing IVF-ICSI treatment","volume":"8","author":"Bentov","year":"2014","journal-title":"Clin Med Insights Reprod Health"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib55","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12958-018-0343-0","article-title":"Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomized controlled trial","volume":"16","author":"Xu","year":"2018","journal-title":"Reprod Biol Endocrinol"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib56","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000513669","article-title":"A novel stimulation protocol for poor-responder patients: combining the stop GnRH-ag protocol with letrozole priming and multiple-dose GnRH-ant: a proof of concept","volume":"86","author":"Orvieto","year":"2021","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib57","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.fertnstert.2016.02.005","article-title":"(Poseidon Group (Patient-Oriented Strategies Encompassing Individualized Oocyte Number). A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept","volume":"105","author":"Alviggi","year":"2016","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib58","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1093\/humrep\/dem270","article-title":"Are GnRH antagonists comparable to agonists for use in IVF?","volume":"22","author":"Huirne","year":"2007","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib59","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.rbmo.2012.11.001","article-title":"GnRH agonist versus GnRH antagonist in ovarian stimulation: an ongoing debate","volume":"26","author":"Orvieto","year":"2013","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib60","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1093\/humrep\/17.9.2287","article-title":"Luteal phase support in infertility treatment: a meta-analysis of the randomized trials","volume":"17","author":"Pritts","year":"2002","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib61","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0015-0282(03)00544-2","article-title":"A new model for ovarian follicular development during the human menstrual cycle","volume":"80","author":"Baerwald","year":"2003","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib62","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.fertnstert.2016.03.002","article-title":"Follicular versus luteal phase ovarian stimulation during the same menstrual cycle (DuoStim) in a reduced ovarian reserve population results in a similar euploid blastocyst formation rate: new insight in ovarian reserve exploitation","volume":"105","author":"Ubaldi","year":"2016","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib63","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1210\/jcem.84.8.5929","article-title":"Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development","volume":"84","author":"Weil","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib64","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1210\/endo-109-4-1303","article-title":"Evidence that granulosa cell aromatase induction\/activation by follicle-stimulating hormone is an androgen receptor-regulated process in-vitro","volume":"109","author":"Hillier","year":"1981","journal-title":"Endocrinology"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib65","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1210\/endo-119-3-1403","article-title":"Androgen modulation of follicle-stimulating hormone-induced granulosa cell steroidogenesis in the primate ovary","volume":"119","author":"Harlow","year":"1986","journal-title":"Endocrinology"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib66","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1080\/09513590.2019.1576621","article-title":"Does double trigger (GnRH-agonist + hCG) improve outcome in poor responders undergoing IVF-ET cycle? A pilot study","volume":"35","author":"Haas","year":"2019","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib67","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1177\/0963689719859539","article-title":"A case series on natural conceptions resulting in ongoing pregnancies in menopausal and prematurely menopausal women following platelet-rich plasma treatment","volume":"28","author":"Pantos","year":"2019","journal-title":"Cell Transplant"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib68","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.3889\/oamjms.2019.825","article-title":"Live birth rates in poor responders' group after previous treatment with autologous platelet-rich plasma and low dose ovarian stimulation compared with poor responders used only low dose ovarian stimulation before in\u00a0vitro fertilization","volume":"7","author":"Stojkovska","year":"2019","journal-title":"Open Access Maced J Med Sci"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib69","doi-asserted-by":"crossref","first-page":"10211","DOI":"10.18632\/aging.103403","article-title":"Effects of intraovarian injection of autologous platelet rich plasma on ovarian reserve and IVF outcome parameters in women with primary ovarian insufficiency","volume":"12","author":"Cakiroglu","year":"2020","journal-title":"Aging"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib70","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4103\/jhrs.JHRS_130_19","article-title":"Combined use of autologous bone marrow-derived stem cells and platelet-rich plasma for ovarian rejuvenation in poor responders","volume":"13","author":"Tandulwadkar","year":"2020","journal-title":"J Hum Reprod Sci"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib71","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4274\/jtgga.galenos.2021.2021.0134","article-title":"The effects of intra-ovarian autologous platelet rich plasma injection on IVF outcomes of poor responder women and women with premature ovarian insufficiency","volume":"23","author":"T\u00fclek","year":"2022","journal-title":"J Turk Ger Gynecol Assoc"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib72","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1093\/humrep\/deab106","article-title":"Intraovarian injection of platelet-rich plasma in assisted reproduction: too much too soon?","volume":"36","author":"Atkinson","year":"2021","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib73","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.fertnstert.2020.07.031","article-title":"Hippo signaling disruption and ovarian follicle activation in infertile patients","volume":"114","author":"Hsueh","year":"2020","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib74","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.fertnstert.2008.03.010","article-title":"Is there a limit for the number of in\u00a0vitro fertilization cycles for an individual patient?","volume":"91","author":"Homburg","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib75","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13048-020-00666-z","article-title":"Does daily co administration of gonadotropins and letrozole during the ovarian stimulation improve IVF outcome for poor and sub optimal responders?","volume":"13","author":"Shapira","year":"2020","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.fertnstert.2022.01.029_bib76","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13048-015-0198-3","article-title":"A simplified universal approach to COH protocol for IVF:\u00a0ultrashort flare GnRH-agonist\/GnRH-antagonist protocol with tailored\u00a0mode and timing of final follicular maturation","volume":"8","author":"Orvieto","year":"2015","journal-title":"J Ovarian Res"}],"container-title":["Fertility and Sterility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028222000644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028222000644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T08:33:28Z","timestamp":1758011608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0015028222000644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0015028222000644"],"URL":"https:\/\/doi.org\/10.1016\/j.fertnstert.2022.01.029","relation":{},"ISSN":["0015-0282"],"issn-type":[{"value":"0015-0282","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pretreatment: Does it improve quantity or quality?","name":"articletitle","label":"Article Title"},{"value":"Fertility and Sterility","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fertnstert.2022.01.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a92022 American Society for Reproductive Medicine, Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}